Chi-Med Signs Collaboration With Lilly For Oncology, Inflammation Candidates

Chi-Med's wholly owned research and development subsidiary Hutchison MediPharma will collaborate with Eli Lilly on the discovery and development of pharmaceutical targets in oncology and inflammation, Chi-Med announced Aug. 20